Welcome to our dedicated page for AETHLON MEDICAL news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on AETHLON MEDICAL stock.
Aethlon Medical Inc. (Nasdaq: AEMD) is an innovative medical technology company dedicated to addressing unmet medical needs in health and biodefense. The company's core focus is on developing the Hemopurifier®, a clinical-stage therapeutic device designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. Aethlon’s proprietary technology, the Aethlon ADAPT™ platform, provides the foundation for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system.
The Hemopurifier®, designated as a breakthrough device by the FDA, has demonstrated broad-spectrum capabilities against exosomes that contribute to the progression of cancer and viruses like HIV and Hepatitis C. Recent developments include ongoing research and clinical trials to evaluate the device's safety and efficacy in removing harmful exosomes and viruses from blood. These trials are taking place in India and Australia, targeting patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Financially, Aethlon Medical reported a cash balance of approximately $8.0 million as of the end of 2023. The company also announced a public offering expected to raise around $4.7 million to support its clinical trials, research, and other corporate needs. The company's leadership, including Interim CEO and CFO Jim Frakes, is committed to advancing the Hemopurifier® and exploring new applications in oncology and infectious diseases.
Partnerships are a crucial aspect of Aethlon’s strategy. The company recently entered into a Materials Transfer Agreement with Santersus AG to explore potential synergies between the Hemopurifier® and Santersus' NucleoCapture devices for the treatment of cancer and organ transplantation. This collaboration aims to enhance the effectiveness of both technologies by combining their capabilities to remove specific harmful agents from the blood.
Overall, Aethlon Medical Inc. is at the forefront of developing groundbreaking medical devices aimed at improving outcomes for patients with severe health conditions, making significant strides in the fields of cancer and infectious diseases.
For more information, visit Aethlon Medical.
Aethlon Medical, Inc. (Nasdaq: AEMD) reported financial results for Q1 ended June 30, 2021, highlighting continued clinical development of the Hemopurifier for COVID-19. The company raised $17.5 million from common stock sales, bringing cash reserves to $25.2 million. Total government contract revenue was approximately $132,000. Operating expenses increased to $2.2 million, leading to a net loss of $2.1 million, up from $1.4 million year-over-year. The company is negotiating with additional clinical centers for trials, with a focus on potential treatments for SARS-CoV-2.
Aethlon Medical, Inc. (AEMD) will announce its first quarter fiscal year 2022 financial results on August 9, 2021, at 4:15 p.m. EST. This will be followed by a conference call at 4:30 p.m. EST to discuss the results and recent corporate developments. The company is known for its Hemopurifier®, a medical device addressing unmet global health needs, particularly in cancer treatment and life-threatening viral infections like COVID-19. The Hemopurifier has received FDA 'Breakthrough Device' designation, allowing for innovative clinical applications and studies.
Aethlon Medical (AEMD) reported financial results for the fiscal year ended March 31, 2021, highlighting a net loss of approximately $7.9 million, up from $6.4 million the previous year. Operating expenses increased to about $8.6 million, driven by higher payroll and clinical trial costs. The company raised around $17.3 million in June 2021 through various financing methods. The Aethlon Hemopurifier showed potential in treating COVID-19 patients, with successful case studies reported. As of March 31, 2021, cash reserves stood at about $9.9 million.
Aethlon Medical (AEMD) will release its financial results for Q4 fiscal year 2021 on June 24, 2021, at 4:15 p.m. ET. Management will also host a conference call at 4:30 p.m. ET the same day to discuss the results and corporate developments. The Hemopurifier, the company’s clinical-stage device, aims to treat cancer and viral infections. It holds FDA designations as a Breakthrough Device for advanced cancer and life-threatening viral infections, including COVID-19.
Aethlon Medical, Inc. (Nasdaq:AEMD) announced a registered direct offering of 1,380,555 shares at $9.00 per share, totaling approximately $12.425 million in gross proceeds. The offering is expected to close on June 14, 2021. Proceeds will be used for working capital and general corporate purposes. Additionally, Aethlon sold 626,000 shares under its At the Market Offering Agreement and will issue 1.12 million shares due to warrant exercises. The Hemopurifier, a key product, is in clinical trials for cancer treatment and COVID-19.
Aethlon Medical (Nasdaq: AEMD) announced a pre-print manuscript detailing two case studies of critically ill COVID-19 patients treated with the Hemopurifier® via Emergency Use. The first patient showed recovery signs despite previous severe viremia and achieved hospital discharge after eight treatments. The second patient demonstrated the in vivo removal of SARS-CoV-2 but unfortunately expired due to disease severity. The company is conducting an Early Feasibility Study, aiming to enroll 40 ICU COVID-19 patients. The Hemopurifier is recognized as a Breakthrough Device for both cancer and life-threatening viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced its participation in two virtual conferences: the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the Maxim Group and M Vest 2021 Emerging Growth Virtual Conference on March 17-18, 2021.
The company’s presentations will include details on the Aethlon Hemopurifier, a device aimed at cancer treatment and viral infections, which holds FDA Breakthrough Device designation. Webcasts will be available on demand starting March 9 at 7:00 a.m. EST.
Aethlon Medical, Inc. (AEMD) reported its financial results for the third quarter ending December 31, 2020. The company had a cash balance of $12.1 million, with government contract revenue increasing to approximately $625,000 from $413,000 year-over-year. Operating expenses surged by 137.9% to $3.07 million, largely due to payroll increases from severance costs and clinical trial expenses. Consequently, the net loss rose to about $2.44 million compared to $821,000 in the same quarter last year. Aethlon continues to develop its Hemopurifier and has initiated clinical trials for COVID-19 and cancer treatments.
Aethlon Medical, Inc. (Nasdaq: AEMD) will release its third quarter fiscal year 2021 financial results on February 10, 2021, at 4:15 p.m. EST. Management will host a conference call at 4:30 p.m. EST to review the results and discuss corporate developments. The Hemopurifier®, Aethlon's immunotherapeutic device, targets cancer and viral infections and has received FDA Breakthrough Device designations. Notably, it is currently being evaluated in a feasibility study for treating COVID-19 patients. Interested parties can register or dial in for the call.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced key executive appointments on January 6, 2021, enhancing its leadership team. Guy Cipriani joins as Senior Vice President and Chief Business Officer, focusing on business development and fundraising, while Dr. Steven LaRosa becomes Chief Medical Officer, overseeing clinical operations for the Hemopurifier®. Cipriani's extensive background includes significant roles at Microbion and Cardiome Pharma, while LaRosa has clinical experience in infectious diseases. The Hemopurifier, an FDA-designated 'Breakthrough Device,' aims to address cancer and severe viral infections.
FAQ
What is the current stock price of AETHLON MEDICAL (AEMD)?
What is the market cap of AETHLON MEDICAL (AEMD)?
What is Aethlon Medical Inc.?
What is the Hemopurifier®?
What are the recent developments for Aethlon Medical?
Who is leading Aethlon Medical?
What are exosomes and why are they important?
How is Aethlon Medical funded?
What collaborations does Aethlon Medical have?
What makes the Hemopurifier® unique?
Where can I find more information about Aethlon Medical?
What are the financial highlights of Aethlon Medical?
